Beta Bionics, Inc. (BBNX)
Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.
Sector: Surgical & Medical Instruments & Apparatus
Industry: Medical - Devices
Beta Bionics, Inc.
No splits on record
Nothing in BBNX's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Revenue | $100.25M | $65.12M | $11.99M | $179K |
| YoY Growth | 53.9% | 442.9% | 6601.1% | - |
| Cost of Revenue | $44.71M | $29.24M | $5.69M | $0 |
| Gross Profit | $55.54M | $35.89M | $6.31M | $179K |
| Gross Margin | 55.4% | 55.1% | 52.6% | 100.0% |
| Research and Development | $34.79M | $26.18M | $17.94M | $31.43M |
| Selling, General, and Administrative | $92.43M | $54.95M | $24.21M | $33.49M |
| Other | $0 | $0 | $0 | $1.1M |
| Total Operating Expenses | $127.22M | $81.14M | $42.16M | $66.02M |
| Operating Income (EBIT) | -$71.68M | -$45.25M | -$35.85M | -$65.84M |
| Operating Margin | -71.5% | -69.5% | -298.9% | -36784.4% |
| Interest Expense | $0 | $0 | $0 | $14K |
| Interest Income | $10.93M | $3.91M | $1.78M | $196K |
| Other Income (Expense) | -$1.52M | -$9.51M | -$8.25M | $1.09M |
| Income Before Tax (EBT) | -$73.2M | -$54.76M | -$44.1M | -$64.75M |
| Income Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$73.2M | -$54.76M | -$44.1M | -$64.75M |
| Net Income Margin | -73.0% | -84.1% | -367.6% | -36173.7% |
| Supplementary Data | ||||
| EPS | -1.81 | -1.28 | -1.03 | -1.51 |
| Diluted EPS | -1.81 | -1.28 | -1.03 | -1.51 |
| Weighted Average OS | 40.53M | 42.86M | 42.86M | 42.86M |
| EBITDA | -$70.32M | -$52.47M | -$42.01M | -$62.66M |
| EBITDA Margin | -70.1% | -80.6% | -350.2% | -35003.9% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Assets | ||||
| Current Assets | ||||
| Cash and Cash Equivalents | $31.58M | $30.43M | $26.57M | $27.68M |
| Short-Term Investments | $187.55M | $73.14M | $70.18M | $0 |
| Cash and Short-Term Investments | $219.13M | $103.58M | $96.75M | $27.68M |
| Accounts Receivable | $19.89M | $12M | $4.45M | $0 |
| Inventory | $21.72M | $13.32M | $1.25M | $0 |
| Other Current Assets | $100K | $1.05M | $275K | $250K |
| Total Current Assets | $267.9M | $132.92M | $103.62M | $28.47M |
| Long-Term Assets | ||||
| Property, Plant & Equipment Net | $15.23M | $11.42M | $6.2M | $6.87M |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 |
| Long-Term Investments | $45.43M | $0 | $100K | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $180K | $5.3M | $121K | $193K |
| Total Long-Term Assets | $60.84M | $16.72M | $6.42M | $7.06M |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $328.74M | $149.65M | $110.04M | $35.53M |
| Liabilities | ||||
| Current Liabilities | ||||
| Accounts Payable | $5M | $2.85M | $1.17M | $430K |
| Short-Term Debt | $0 | $0 | $1.22M | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $1.56M | $939K | $87K | $0 |
| Other Current Liabilities | $14.59M | $10.94M | $2.65M | $5.57M |
| Total Current Liabilities | $30.92M | $21.15M | $10.61M | $8.87M |
| Long-Term Liabilities | ||||
| Long-Term Debt | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $3.3M | $1.86M | $255K | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $1.55M | $44.9M | $37.57M | $193.53M |
| Total Long-Term Liabilities | $10.21M | $52.48M | $40.83M | $196.69M |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Total Liabilities | $41.13M | $73.63M | $51.43M | $205.56M |
| Stockholders' Equity | ||||
| Preferred Stock | $0 | $321.37M | $261.71M | $0 |
| Common Stock | $4K | $1K | $1K | $1K |
| Retained Earnings | -$369.94M | -$296.74M | -$229.66M | -$185.56M |
| Comprehensive Income & Other | $403K | $65K | $137K | $0 |
| Other Stockholders' Equity | $657.54M | $372.75M | $288.27M | $15.53M |
| Total Equity | $287.61M | $76.01M | $58.61M | -$170.03M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $328.74M | $149.65M | $110.04M | $35.53M |
| Supplementary Data | ||||
| Total Debt | $7.3M | $7.25M | $4.22M | $4.13M |
| Net Debt | -$24.27M | -$23.18M | -$22.34M | -$23.54M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Currency | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
| Operating Activities | ||||
| Net Income | -$73.2M | -$54.76M | -$44.1M | -$64.75M |
| Depreciation & Amortization | $2.88M | $2.28M | $2.09M | $2.09M |
| Deferred Income Tax | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $16.38M | $6.38M | $5.66M | $6.1M |
| Changes in Working Capital: | ||||
| Accounts Receivable | -$5.16M | -$7.62M | -$4.49M | $0 |
| Inventory | -$9.88M | -$11.44M | -$1.19M | $0 |
| Accounts Payable | $2.1M | $1.51M | $716K | -$77K |
| Other Working Capital | $3.95M | $5.39M | -$340K | -$2.71M |
| Total Working Capital Change | -$8.99M | -$12.15M | -$5.3M | -$2.79M |
| Other Non-Cash Items | $12.01M | $9.96M | $9.21M | -$854K |
| Net Cash from Operating | -$50.92M | -$48.27M | -$32.45M | -$60.21M |
| Investing Activities | ||||
| Capital Expenditures | -$5.3M | -$3.4M | -$402K | -$772K |
| Acquisitions | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$327.51M | -$72.13M | -$69.3M | $0 |
| Sales of Investments | $170M | $72M | $0 | $0 |
| Other Investing Activities | $0 | $50K | $4K | $3K |
| Net Cash from Investing | -$162.81M | -$3.48M | -$69.69M | -$769K |
| Financing Activities | ||||
| Debt Repaid | - | - | - | - |
| Common Stock Issuance | $214.87M | $102K | $29K | $389K |
| Common Stock Repurchases | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Financing Activities | $0 | -$4.15M | $0 | $0 |
| Net Cash from Financing | $214.87M | $55.62M | $101.03M | $56.78M |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $1.14M | $3.87M | -$1.11M | -$4.2M |
| Supplementary Data | ||||
| Operating Cash Flow | -$50.92M | -$48.27M | -$32.45M | -$60.21M |
| Capital Expenditure | -$5.3M | -$3.4M | -$402K | -$772K |
| Free Cash Flow | -$56.22M | -$51.67M | -$32.85M | -$60.98M |
| Cash at Beginning | $30.53M | $26.67M | $27.77M | $31.97M |
| Cash at End | $31.68M | $30.53M | $26.67M | $27.77M |